Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 456

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 456
---
 coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government -fundedprograms may result in a similar reduction in payments from private payors. The implementation of current and future cost containment measures or other healthcare reforms may adversely affect our operations and prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. 254

MANAGEMENT OF PROFUSA Executive Officers and Directors Profusa is managed by its board of directors. Directors are elected by the shareholders of Profusa holding a majority of the issued and outstanding shares of stock in Profusa at an annual meeting of the shareholders and hold office until the their respective term expires after their election or until their successors are elected and qualified. A director may resign at any time and may be removed by the shareholders holding a majority of the issued and outstanding shares of stock entitled to vote in Profusa. Any vacancies on the Board of Directors may be filled by the unanimous vote of the remaining directors. A director elected to fill such vacancy will serve the unexpired term of his predecessor in office. The number of directors serving on the Board of Directors may be increased or decreased by the Board of Directors. The directors and executive officers as of the date of this proxy statement/prospectus are as follows:

| Name                    |     | Age |     | Position                                       |
| Executive Officers:     |     |     |     |                                                |
| Ben C. Hwang, Ph.D.     |     |  57 |     | Chairman of the Board; Chief Executive Officer |
| Non-Employee Directors: |     |     |     |                                                |
| Joan Braddi             |     |  68 |     | Director                                       |
| Qianye Karen Liu, Ph.D. |     |  54 |     | Director                                       |
| Siu Wai Ng              |     |  38 |     | Director                                       |

Executive Officers Ben C. Hwang, Ph.D.— Dr. Hwang has served as Profusa’s Chairman of the Board and Chief Executive Officer since January 2012. Prior to Profusa, Dr. Hwang served in a variety of leadership roles at Life Technologies Corp. (acquired by Thermo Fisher Scientific, Inc.), including President of the Asia Pacific Region and Head of the qPCR Division. Prior to joining Life Technology, Dr. Hwang was a consultant with McKinsey & Company. Dr. Hwang received his M.A. in Biology and